NCT04134312 is a Phase 1 clinical trial of MVA-BN-Brachyury in Solid Metastatic Tumor, sponsored by Bavarian Nordic.

Who is sponsoring NCT04134312?

NCT04134312 is sponsored by Bavarian Nordic.

What drugs are being tested in NCT04134312?

Interventions in NCT04134312: MVA-BN-Brachyury.

What condition does NCT04134312 study?

NCT04134312 studies Solid Metastatic Tumor.

Is NCT04134312 still recruiting?

NCT04134312 is currently completed. Last updated 14 July 2021.

Last reviewed 2021-07-14 · How we verify

NCT04134312

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Completed Phase 1 Last updated 14 July 2021

What this trial tests

Phase 1 trial testing MVA-BN-Brachyury in Solid Metastatic Tumor in 13 participants. Completed in 6 April 2021.

Timeline

8 January 2020

Primary endpoint
12 January 2021

6 April 2021

Quick facts

Lead sponsor	Bavarian Nordic
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	13
Start date	8 January 2020
Primary completion	12 January 2021
Estimated completion	6 April 2021
Sites	1 location across United States

Drugs / interventions tested

MVA-BN-Brachyury — full drug profile →

Conditions studied

Solid Metastatic Tumor — all drugs for Solid Metastatic Tumor →

Sponsor

Bavarian Nordic — full company profile →

Who can join

18 and older, any sex, with Solid Metastatic Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. Patients with metastatic or unresectable locally advanced malignant solid tumors will be enrolled and treated according to a 3+3 dose escalation scheme. Up to 3 dose levels will be explored. Patients will receive MVA-BN-Brachyury every three weeks, three administrations in total. Patients will be hospitalized after each vaccination, over 48 hours. Trial duration will be approximately 24 weeks per patient including 3 months after the last vaccination follow up (FU) period.

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications.
Wang L, Jin Z, Master RP, Maharjan CK, et al · · 2022 · cited 29× · PMID 35805056 · DOI 10.3390/cancers14133287
Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer.
DeMaria PJ, Lee-Wisdom K, Donahue RN, Madan RA, et al · · 2021 · cited 26× · PMID 34479925 · DOI 10.1136/jitc-2021-003238
The role of tumor immune microenvironment in chordoma: promising immunotherapy strategies.
Xu J, Shi Q, Wang B, Ji T, et al · · 2023 · cited 14× · PMID 37720221 · DOI 10.3389/fimmu.2023.1257254
Personalized nanovaccines for treating solid cancer metastases.
Feng T, Hu J, Wen J, Qian Z, et al · · 2024 · cited 7× · PMID 39609851 · DOI 10.1186/s13045-024-01628-4
Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy.
Han R, Zhou H, Peng B, Yu S, et al · · 2025 · cited 3× · PMID 40573881 · DOI 10.3390/vaccines13060550
Fast Clearance of the SARS-CoV-2 Virus in a Patient Undergoing Vaccine Immunotherapy for Metastatic Chordoma: A Case Report.
Pastor DM, Lee-Wisdom K, Arai AE, Sirajuddin A, et al · · 2020 · cited 2× · PMID 33330104 · DOI 10.3389/fonc.2020.603248

Verify or expand the search:

Other trials of MVA-BN-Brachyury

Trials testing the same drug.

NCT04020094 — Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Can · Phase 2 · withdrawn
NCT03493945 — Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) · Phase 1, PHASE2 · completed

Other Bavarian Nordic trials

Trials by the same sponsor.

NCT07199569 — Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells · Phase 2 · active not recruiting
NCT06549530 — Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children From 2 Years to Less Than 12 Years · Phase 2 · active not recruiting
NCT05329220 — ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 · Phase 3 · completed
NCT05349617 — Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years · Phase 3 · completed
NCT05238025 — MVA-BN-RSV Vaccine Trial · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04134312 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bavarian Nordic
Last refreshed: 14 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04134312.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing